IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA

QR Code

IMPACT OF LENALIDOMIDE MAINTENANCE DOSAGE ON SURVIVAL OUTCOMES IN MULTIPLE MYELOMA

Objective: This study aimed to assess the impact of lenalidomide maintenance dosing on clinical outcomes and the development of lenalidomide refractoriness in Multiple Myeloma (MM) patients who received maintenance therapy following Autologous Stem Cell Transplantation (ASCT) at our institution. Met...

Full description

Saved in:

Bibliographic Details
Main Authors:	Zeynep Kürüm, Ayfer Gedük
Format:	Article
Language:	English
Published:	Elsevier 2025-07-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137925001713
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenalidomide for relapsed or refractory multiple myeloma
by: S. S. Bessmeltsev1, et al.
Published: (2014-07-01)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
by: Johan Lund, et al.
Published: (2018-06-01)

Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
by: I. G. Rekhtina, et al.
Published: (2019-04-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials.
by: Bo Yang, et al.
Published: (2013-01-01)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015-03-01)

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial
by: Sara Bringhen, et al.
Published: (2025-07-01)

Three-year progression-free survival of a patient with concomitant mucinous adenocarcinoma of the colon with peritoneal dissemination and multiple myeloma who received lenalidomide: a case report
by: Koki Tamai, et al.
Published: (2024-02-01)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024-05-01)

Impact of treatment delay of multiple myeloma bone disease on later myeloma-related skeletal events and outcome
by: Eskelinen Veera, et al.
Published: (2025-08-01)

Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US
by: Niodita Gupta-Werner, et al.
Published: (2025-07-01)

Lenalidomide and its impact on exanthematous reactions: a case report
by: Cristiana Vieira-Maia, et al.
Published: (2025-04-01)

Multiple Myeloma and Dentistry
by: Shah, Ajaz, et al.
Published: (2012)

Very good partial remission predicts progression-free survival in patients with multiple myeloma
by: A. S. Luchinin, et al.
Published: (2024-01-01)

The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients
by: Shohei Mizuno, et al.
Published: (2025-07-01)

Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients
by: Naomi van Hest, et al.
Published: (2023-01-01)

Regulatory Cells and Multiple Myeloma
by: Raja, Karthick Raja Muthu, et al.
Published: (2012)

Renal Disease in Multiple Myeloma
by: Saydam, Guray, et al.
Published: (2012)

Modern therapy of multiple myeloma
by: O. M. Votyakova
Published: (2008-12-01)

The role of Capon in multiple myeloma
by: Yaodong Shen, et al.
Published: (2017-06-01)

Multiple Myeloma with Intracranial Distribution
by: A. Yu. Rynda, et al.
Published: (2023-06-01)

Comorbidities in patients with multiple myeloma
by: L. P. Kuznetsova, et al.
Published: (2019-08-01)

Review of the Expert Council “Multiple myeloma: the era of monoclonal antibodies in the treatment of patients with multiple myeloma”
by: M. I. Akhmedov, et al.
Published: (2024-01-01)

Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma
by: Ai-Xin Hu, et al.
Published: (2017-04-01)

Cancer Stem Cells in Multiple Myeloma
by: Ciavarella, Sabino, et al.
Published: (2011)

Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Crawford, Lisa J., et al.
Published: (2012)

Stem Cell Mobılızatıon in Multıple Myeloma
by: Bakanay, Şule Mine, et al.
Published: (2012)

Onset of multiple myeloma with rheumatic polymyalgia
by: E. R. Israelyan, et al.
Published: (2019-12-01)

IMMUNE DISTURBANCES IN PATIENTS WITH MULTIPLE MYELOMA
by: E. A. Senkina, et al.
Published: (2014-07-01)

Pitfalls in the pathological diagnosis of multiple myeloma
by: V. V. Baykov
Published: (2022-11-01)

Treatment of double-refractory multiple myeloma
by: S. V. Semochkin
Published: (2021-09-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Neutrophilic hyperleukocytosis in the multiple myeloma onset
by: I. G. Rekhtina, et al.
Published: (2022-07-01)

Expert Council Review “Multiple myeloma”
by: M. I. Akhmedov, et al.
Published: (2023-05-01)

Bone marrow adipocytes and multiple myeloma
by: A. A. Philchenkov
Published: (2019-04-01)

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Danai Dima, et al.
Published: (2025-06-01)

Case report: pomalidomide as maintenance after salvage autologous stem cell transplantation in a patient with relapsed multiple myeloma
by: S. V. Semochkin, et al.
Published: (2023-12-01)

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma [Letter]
by: Gupta-Werner N, et al.
Published: (2025-07-01)

Challenges, Difficulties, and Delayed Diagnosis of Multiple Myeloma
by: Tugba Zorlu, et al.
Published: (2025-07-01)